linjc16/ctgov huggingface dataset:
Mini-fluid Challenge as a Predictor of Fluid Response for Pneumoperitoneum Patient

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate whether the change of stroke volume index(△SVI) induced by the rapid mini-fluid administration can predict fluid responsiveness in patients with pneumoperitoneum

Detailed Description
-----------------
Perioperative fluid management is significant important during surgery. The current trend tends to use goal-directed fluid therapy in surgery. Goal-directed fluid therapy refers to continuous monitoring of hemodynamic parameters during surgery and managing more accurate fluid administration based on the data obtained while promoting optimal tissue perfusion. Define fluid responsiveness with the hemodynamic parameters as to whether the cardiac output can be significantly increased after administration of fluid. Therefore, the advantage of predicting fluid responsiveness is that it can optimize the cardiac output and tissue perfusion while avoiding administering unnecessary fluid to patients. The purpose of this study is to evaluate whether the change of stroke volume index(△SVI) induced by the rapid mini-fluid administration can predict fluid responsiveness in patients with pneumoperitoneum.

Official Title
-----------------
Mini-fluid Challenge as a Predictor of Fluid Response for Pneumoperitoneum Patient

Conditions
-----------------
Anesthesia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: receive operation that required pneumoperitoneum and FloTrac monitoring ASA 1 3 age between 20 to 70 year old Exclusion Criteria: patient who cannot understand the process and aim of the study patient with arrhythmia poor heart function(LVEF<50%, severe valvular disease, CAD) CKD pregnant patient patients allergic to voluven

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change of stroke volume index | record stroke volume index before and after mini-fluid challenge | 1 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
mini-fluid challenge
Naturalistic Study Into the Hangover Effects of MDMA

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to compare hangover effects of MDMA users versus those who used other drugs, or alcohol only at New Year's Eve. The week after New Years Eve, every day participants complete a questionnaire about the presence and severity of potential hangover symptoms. At day 1, demographics and alcohol and drug use at New Years Eve were recorded. On day 7, the Brief Symptom Inventory (BSI) is completed to asses last weeks mood. After 4 weeks, after a drug-free week, the BSI is completed again to serve as a reference.

Detailed Description
-----------------
A convenience sample was invited by e-mail to participate in the study, via the organizer of a private New Years Party.It was attempted to include as much participants as possible. Hence, no sampling method was applied when recruiting participants.

Official Title
-----------------
A Naturalistic Study Comparing the Hangover Effects of MDMA, Other Drugs, and Alcohol in a Sample of Recreational Polydrug Users

Conditions
-----------------
Hangover

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: poly drug user 18+ years old Exclusion Criteria: mental or physical illness

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| MDMA<br>poly drug users that used MDMA at New Years Eve | |
| Other Drugs<br>poly drug users that used drugs at New Years Eve, but not MDMA | |
| Alcohol<br>poly drug users that used no drugs at New Years Eve, but did consume alcohol | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hangover, next day effects, MDMA, Alcohol
Graduated Embryo Score (GES) in the Fresh Cycle Predicts Outcome From Frozen Embryo Transfer

Study Overview
=================
Brief Summary
-----------------
Evaluation of embryo quality in the fresh cycle as a predictor of outcome from frozen embryo transfer.

Detailed Description
-----------------
Outcomes from frozen embryo transfer reviewed based on the quality of the embryos in the ftresh cycle as assessed by the Graduatede embryo score.

Official Title
-----------------
Graduated Embryo Score (GES) Int he Fresh Cycle Predicts Outcome From Frozen Embryo Transfer

Conditions
-----------------
Infertility

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 2 frozen blastocysts

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 44 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>Patients with 2 or more frozen blastocyst that scored GES 70 or better in the fresh cycle. | |
| 2<br>Patients with 2 or more frozen blastocysts scoring GES <70 in the fresh cycle. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| On-going gestation (beyond 8 wks) |  | Fetal heart activity at 8 weeks of gestation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Implantation rate (gestational sacs/ embryos transferred) |  | 8 weeks of gestation | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cryopreservation, Frozen embryo transfer, Graduated Embryo Score
Pharmaceutical Care for Diabetes Type 2 Patients: a Randomised Controlled Trial

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to evaluate the therapeutic effectiveness and cost-effectivity of pharmaceutical care for diabetes type 2 patients. Patients will be randomly allocated to the control group ( = no input from pharmacist) or intervention group ( = with pharmaceutical care at baseline and follow-up visits over 6 months).

Official Title
-----------------
Pharmaceutical Care for Diabetes Type 2 Patients: a Randomised Controlled Trial

Conditions
-----------------
Diabetes Mellitus

Intervention / Treatment
-----------------
* Procedure: Pharmaceutical care at baseline and follow-up visits over 6 months


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 45-75 years Body Mass Index >= 25 Diabetes treatment for at least 12 months Regular visitors of the participating community pharmacy Exclusion Criteria: Patients taking only insulin (no oral antidiabetic drugs)

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Pharmaceutical care at baseline and follow-up visits over 6 months|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The difference between the study groups in the change of blood glucose and HbA1c |  | baseline and after 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Knowledge about diabetes and treatment |  | after 6 months | 
| Therapy adherence |  |  | 
| Body Mass Index |  | after 6 months | 
| Periods of severe hypoglycemia |  |  | 
| GP visits, emergency room visits and hospitalisations |  |  | 
| Work days lost |  |  | 
| Frequency of eye and foot examination |  |  |
Venous Obstruction in Neurodegenerative Disorders Research Registry

Study Overview
=================
Brief Summary
-----------------
To establish if there are venous obstructions in patients with neurodegenerative disorders

Detailed Description
-----------------
This research registry will observe the venous obstruction in neurodegenerative disorders. This will provide data that will allow researchers to classify abnormal valve and venous morphology, distinguish vessels which are more responsive to treatment, determine groups who respond more favorably to treatment, and overall evaluate the outcomes of venous angioplasty in various neurodegenerative disorders that involve venous obstruction.

Official Title
-----------------
Venous Obstruction in Neurodegenerative Disorders Research Registry

Conditions
-----------------
Chronic Cerebral Spinal Venous Insufficiency

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ability to comprehend the nature of the study, including the risks and benefits and execute an informed consent Males or Females between the ages of 18 and 90 years of age Voluntary agreement to participate in the Venous Obstructions in Neurodegenerative Diseases Research Registry Exclusion Criteria: Any implantable/metallic objects that prevent subject from having a magnetic resonance imaging ( MRI/MRV) study History of uncontrolled hypertension Previous venous angioplasty treatment for Chronic cerebral spinal venous insufficiency Special Populations. Special groups include, but are not limited to children, prisoners, pregnant women,fetuses, and cognitively impaired individuals who are unable to provide informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
CCSVI
Safety and Effectiveness of Nivolumab in Recurring Kidney Cancer Participants

Study Overview
=================
Brief Summary
-----------------
A non-interventional, medical record review of clinical data collected from Japanese participants with recurring kidney cancer

Official Title
-----------------
Efficacy and Safety of Nivolumab in Metastatic Renal Cell Cancer Patients - Japanese Real-World Data Through Clinical Chart Review

Conditions
-----------------
Kidney Cancer, Renal Cancer

Intervention / Treatment
-----------------
* Other: Non-Interventional


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: A patient with RCC with distant metastasis treated for the first time with nivolumab Exclusion Criteria: Patients who have participated in some trials with immuno-checkpoint blockade before or after treatment with nivolumab after diagnosis with RCC Other protocol defined inclusion/exclusion criteria could apply
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Participants with metastatic RCC taking nivolumab<br>Specified dose on specified day | Other: Non-Interventional<br>* Non-Interventional<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall survival status |  | 6 months | 
| Overall survival status |  | 36 months | 
| Best overall response |  | 6 months | 
| Best overall response |  | 36 months | 
| Progression free survival rate |  | 6 months | 
| Progression free survival rate |  | 36 months | 
| Disease free survival |  | 6 months | 
| Disease free survival |  | 36 months | 
| Objective response rate |  | 6 months | 
| Objective response rate |  | 36 months | 
| Duration of response |  | 6 months | 
| Duration of response |  | 36 months | 
| Incidence of adverse events |  | 36 months | 
| Incidence of serious adverse events |  | 36 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Distribution of clinical characteristics |  | 36 months | 
| Distribution of socio-demographic characteristics |  | 36 months |
Meropenem Versus Meropenem Plus Glycopeptide in Patients With Febrile Neutropenia After Allogenic Blood Stem Cell Transplantation

Study Overview
=================
Brief Summary
-----------------
Observational study to compare the treatment in neutropenic patients after allogenic blood stem cell transplantation, with meropenem or meropenem plus glycopeptide.

Detailed Description
-----------------
Observational study cost-effectivity to compare the treatment in neutropenic patients after allogenic blood stem cell transplantation, with meropenem or meropenem plus glycopeptide. The study will be done in two consecutive cohorts of patients. First cohort: meropenem 1g/8h ev Second cohort: meropenem 1g/8h and glycopeptide (vancomycin 1g/12 h or teicoplanin 400 mg/24h)

Official Title
-----------------
MERONEM: Observational Study About Efficacy of Meropenem in Comparison of Meropenem and Glycopeptide in Treatment of Neutropenia Febrile in Allogenic Blood Stem Cell Transplantation Patients

Conditions
-----------------
Allogenic Blood Stem Cell Transplantation, Febrile Neutropenia

Intervention / Treatment
-----------------
* Drug: Meropenem
* Drug: Vancomycin
* Drug: Teicoplanin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years Patients submitted to allogenic transplant Neutropenia: neutrophils account < 500/mm3 or neutrophils account < 1000/mm3 with prevision to decrease until 500/mm3 at the next 24-48 h Signs and symptoms to infection Fever: Temperature> 38,3 ºC registered one time, or 38 ºC en two times separated 60 minutes in a period of 12 h. Exclusion Criteria: Medical history of meropenem or glycopeptides hypersensitivity Renal failure or creatinine in serum > 2,25 mg/dl or creatinine clearance < 40 ml Liver insufficiency Childbearing potential or breast feeding period Contraindications to meropenem, vancomycin or teicoplanin

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Meropenem|antibiotic|
|Drug: Vancomycin|Antibiotic|
|Drug: Teicoplanin|Antibiotic|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Febrile neutropenia
Sleep Disordered Breathing and Diabetes

Study Overview
=================
Brief Summary
-----------------
The hypothesis of this study is: sleep disordered breathing (SDB), specifically, obstructive sleep apnea, is associated with poorer glucose in the existing type 2 diabetic condition. In an exploration of this hypothesis, the investigators hope to provide evidence linking SDB to increased severity of disease in the type 2 diabetic patient. By doing so, the investigators ultimately seek to support investigating the use of SDB interventions as an additional method of care in the treatment of type 2 diabetes.

Official Title
-----------------
Sleep Disordered Breathing and Blood Glucose Control in Type 2 Diabetes

Conditions
-----------------
Type 2 Diabetes, Obstructive Sleep Apnea

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult female and male patients with type 2 diabetes who are followed by University of Chicago physicians Exclusion Criteria: patients with the diagnosis of type 1 diabetes (DM); newly diagnosed Type 2 DM patients patients with the diagnosis of OSA using CPAP for either 4 or more hours per night or 5 nights per week

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Stable type 2 Diabetes (ST2D)<br>Adults with Type 2 diabetes who receive medical care at the University of Chicago | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement in glucose tolerance |  | Day 1 to day 10. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Type 2 diabetes,, obstructive sleep apnea
Factors Associated With Post-induction Hypotension in iNPH Patient Undergoing VP and LP Shunt

Study Overview
=================
Brief Summary
-----------------
This study is a retrospective work involving the review of patients who were scheduled for VP or LP shunt in Siriraj Hospital, Mahidol University, Thailand. The sample size calculation was based on the rule of thumbs of the logistic regression comprising 18 risk factors. The incidence of post-induction hypotension according to our institution's pilot study November 2019-January 2020) was 47%. With 10% addition for missing data and other possible reasons, the sample size was 426. The primary objective of the study is to report the factors associated with post-induction hypotension in iNPH patients undergoing VP or LP shunt procedures. Our secondary objective is to determine the incidence of post-induction hypotension in these patients.

Official Title
-----------------
Factors Associated With Post-induction Hypotension in Idiopathic Normal Pressure Hydrocephalus (iNPH) Patient Undergoing Ventriculoperitoneal (VP) and Lumbar Peritoneal (LP) Shunt

Conditions
-----------------
The iNPH Patients Scheduled for VP or LP Shunt Procedures

Intervention / Treatment
-----------------
* Drug: Ehedrine Norepineprine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Elective cases of iNPH scheduled for VP and LP shunt Patients aged > 18 years old Exclusion Criteria: Emergency cases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hypotensive group<br>Hypotenson is defined as systolic blood pressure (SBP) < 80 mmHg or a drop more than 20% from baseline SBP for longer than 10 minutes or a drop that requires treatment either vasopressor or inotropic drugs. | Drug: Ehedrine Norepineprine<br>* No interventions required considering that this was a retrospective study.<br>|
| Non-hypotensive group<br>The pateints who did not develop hypotensive episodes as aforementioned. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Factors associated with post-induction hypotension in iNPH patients undergoing VP or LP shunt procedures | Risk factors associated with post-induction hypotension after administration of anesthetic agents | 9 months |
Evaluation of BD Glucan in Peritoneal Fluid for the Diagnosis of Fungal Peritonitis

Study Overview
=================
Brief Summary
-----------------
Invasive candidiasis has a high mortality rate, around 40%. Outcome remains tightly linked to the time of treatment administration. Routine microbiological techniques give results too lately to allow prompt antifungal therapy initiation (at least 48 hours). It is important to develop diagnostic tools to initiate antifungal therapy as early as possible. The B D glucan detection, one of the major components of the candida cell wall, can be useful for a early diagnosis. There are several techniques on the market for the detection of glucan. In Europe and America, the most used is Fungitell (Associated of Cape Cod, Inc). There is several studies about the use of such kits for fungemia. A number of studies are reporting evidences of a early diagnosis. But, in medical literature, there isn't study focused on the detection of B D glucan in peritoneal fluid for Candida peritonitis diagnosis.

Official Title
-----------------
Evaluation of the Detection of B D Glucan in Peritonitis Fluid in Intensive Care Unit (ICU) Patients With Peritonitis for the Diagnosis of Fungal Peritonitis, Compared to Routine Microbiology Diagnosis Method. The PERICAND Study

Conditions
-----------------
Adult Patient (Over 18 Yr-old) Admitted to the ICU for Acute Peritonitis

Intervention / Treatment
-----------------
* Other: Intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged ≥ 18 years old written informed consent for inclusion in the study stay in intensive care unit diagnosed with a peritonitis peritoneal fluid collected by a surgery or radiology procedure, analysed at bacteriology laboratory of l'institut des agents infectieux, l'hôpital de la Croix Rousse Exclusion Criteria: Pregnant woman Moribund patient

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| intervention<br>Adult patient (over 18 yr-old) admitted to the ICU for acute peritonitis with a peritoneal fl:uid sample obtained via surgery or radiological drainage | Other: Intervention<br>* Evaluation of sensibility, specificity, negative and positive predictive value of BD glucan in peritoneal fluid for diagnosis of fungal peritonitis, compared with fungal culture<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of sensibility, specificity, negative and positive predictive value of BD glucan in peritoneal fluid for diagnosis of fungal peritonitis, compared with fungal culture | Evaluation of sensibility, specificity, negative and positive predictive value of BD glucan in peritoneal fluid for diagnosis of fungal peritonitis, compared with fungal culture | 1 year |